文献速递肝病消化道肿瘤与早癌

双特异性酪氨酸磷酸化调节激酶3缺失激活嘌呤代谢并促进肝细胞癌进展

Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.
PubMed 文献 · Hepatology · 2019-06-21

在肝细胞癌中Dyrk3显著下调,过表达Dyrk3可抑制异种移植瘤生长与转移。机制上Dyrk3磷酸化NCOA3 Ser-1330,破坏其与ATF4结合并抑制ATF4转录活性,从而下调嘌呤代谢;ATF4反过来负调控Dyrk3启动子,形成双负反馈环路。人肝癌标本中Dyrk3及磷酸化NCOA3-S1330与ATF4表达呈负相关,提示Dyrk3/NCOA3/ATF4轴是潜在治疗靶点。

要点

  • Dyrk3在肝细胞癌中显著下调,过表达可抑制肿瘤生长和转移。
  • Dyrk3通过磷酸化NCOA3 Ser-1330抑制ATF4转录活性,下调嘌呤代谢。
  • Dyrk3/NCOA3/ATF4轴在人肝癌标本中表达负相关,为潜在治疗候选。

核心结论

  • Dyrk3通过负调控NCOA3/ATF4转录因子复合物重编程肝细胞癌代谢,并鉴定NCOA3为Dyrk3的磷酸化底物,提示Dyrk3/NCOA3/ATF4轴是肝细胞癌治疗的潜在候选靶点。

研究设计与样本

  • 基础研究:在肝细胞癌细胞与异种移植肿瘤模型中探索Dyrk3的作用,并进行代谢物质谱分析及人肝细胞癌标本表达相关性分析。

主要发现

  • Dyrk3在肝细胞癌中较正常对照显著下调,在肝细胞癌细胞中引入Dyrk3可显著抑制异种移植肿瘤模型中的肿瘤生长和转移。
  • 代谢物质谱分析提示Dyrk3的作用至少部分通过下调嘌呤代谢实现,抑制嘌呤合成可逆转Dyrk3缺失介导的肝细胞癌进展。
  • Dyrk3敲低的作用需要NCOA3,NCOA3作为ATF4共激活因子靶向嘌呤通路基因进行转录激活。
  • Dyrk3直接磷酸化NCOA3 Ser-1330,破坏其与ATF4结合并抑制ATF4转录活性;磷酸化抵抗的NCOA3-S1330A突变体具有相反效应。
  • ATF4负调控Dyrk3启动子活性,形成双负反馈环路;人肝细胞癌标本中Dyrk3和磷酸化NCOA3-S1330水平与ATF4表达呈负相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer cells metabolize different energy sources to generate biomass rapidly. The purine biosynthetic pathway was recently identified as an important source of metabolic intermediates for these processes. However, very little was known about the regulatory mechanisms of purine metabolism in hepatocellular carcinoma (HCC). We explored the role of dual-specificity tyrosine (Y) phosphorylation-regulated kinase 3 (Dyrk3) in HCC metabolism. Dyrk3 was significantly down-regulated in HCC compared with normal controls. Its introduction in HCC cells markedly suppressed tumor growth and metastasis in xenograft tumor models. Mass spectrometric analysis of metabolites suggests that the effect of Dyrk3 on HCC occurred at least partially through down-regulating purine metabolism, as evidenced by the fact that inhibiting purine synthesis reverted the HCC progression mediated by the loss of Dyrk3. We further provide evidence that this action of Dyrk3 knockdown requires nuclear receptor coactivator 3 (NCOA3), which has been shown to be a coactivator of activating transcription factor 4 (ATF4) to target purine pathway genes for transcriptional activation. Mechanistically, Dyrk3 directly phosphorylated NCOA3 at Ser-1330, disrupting its binding to ATF4 and thereby causing the inhibition of ATF4 transcriptional activity. However, the phosphorylation-resistant NCOA3-S1330A mutant has the opposite effect. Interestingly, the promoter activity of Dyrk3 was negatively regulated by ATF4, indicating a double-negative feedback loop. Importantly, levels of Dyrk3 and phospho-NCOA3-S1330 inversely correlate with the expression of ATF4 in human HCC specimens. Conclusion: Our findings not only illustrate a function of Dyrk3 in reprograming HCC metabolism by negatively regulating NCOA3/ATF4 transcription factor complex but also identify NCOA3 as a phosphorylation substrate of Dyrk3, suggesting the Dyrk3/NCOA3/ATF4 axis as a potential candidate for HCC therapy.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ma F, Zhu Y, Liu X, et al. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression. Hepatology. 2019. PMID: 31066068. doi:10.1002/hep.30703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。